Analytical methods updated to ICH Q2(R2)

The International Council for Harmonisation adopted the revised ICH Q2(R2), Validation of Analytical Procedures, at Step 4 in November 2023, replacing the earlier Q2(R1). The revision consolidates the previously separate Q2 text into a single, modernised guideline and broadens its scope beyond conventional chromatographic and spectroscopic methods. It restates the core validation characteristics — specificity/selectivity, accuracy, precision (repeatability and intermediate precision), detection and quantitation limits, linearity/response, and range — and it is intended to be read alongside the analytical-development concepts described elsewhere in the ICH quality series. Ergopharm has treated the Step 4 text as the reference standard for its own method-validation work.

“Aligning our validation practice to ICH Q2(R2) reflects Ergopharm's commitment to demonstrating that every analytical procedure is fit for its intended purpose.”

Over the first half of 2024, Ergopharm's quality-control function revised its master validation protocols and standard operating procedures to reflect the Q2(R2) structure and terminology. Assay, related-substances and dissolution methods for the company's sterile injectable and oral-solid lines are being brought under the updated framework, with validation summary reports written to demonstrate each characteristic against pre-defined acceptance criteria. The programme is documented through Ergopharm's own change-control system, so that each method transition carries a traceable record of the protocol, the raw data reviewed, and the Qualified Person's sign-off before a method is released for routine use.

The work is being sequenced against the impurity and quantitative-limits requirements that these methods support, including the related-substances thresholds framed by ICH Q3A and Q3B and, where relevant, residual-solvent and elemental-impurity determinations under Q3C and Q3D. Method robustness and system-suitability parameters are recorded within each Batch Manufacturing Record and Certificate of Analysis workflow, and results feed the company's stability studies conducted under the ICH Q1A(R2) storage conditions. All data are captured under Ergopharm's ALCOA+ data-integrity controls.

Ergopharm notes that ICH Q2(R2) is a harmonised technical guideline, not a marketing authorisation, and that alignment to it describes the company's internal validation practice rather than any national regulatory approval. The updated methods form part of Ergopharm's continued-process-verification activities and its wider Pharmaceutical Quality System commitments under ICH Q10. The figures and timelines described here are illustrative of the company's own processes.